Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market. Learn more on RHHBY stock here.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received ... Poseida - equivalent to 66% of the California company's stock - which had been tendered by shareholders at a price ...

ROCHE HOLDING AG (ADR) (RHHBY) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock ...

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.